- Home
- ORIC
as 07-11-2025 4:00pm EST
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 362.9M | IPO Year: | 2020 |
| Target Price: | $18.29 | AVG Volume (30 days): | 964.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.67 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | ORIC | Chief Financial Officer | Jun 23 '25 | Sell | $10.17 | 33,500 | $351,383.60 | 100,783 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Jun 12 '25 | Sell | $10.00 | 300 | $3,000.00 | 100,783 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Jun 10 '25 | Sell | $10.00 | 3,300 | $33,017.00 | 100,783 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Jun 6 '25 | Sell | $10.00 | 2,900 | $29,021.32 | 100,783 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 06/24/2025
Zacks
24 days ago
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
Zacks
24 days ago
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
Zacks
a month ago
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
TipRanks
a month ago
JPMorgan biotech/pharma analysts hold analyst/industry conference call
GlobeNewswire
a month ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
Zacks
a month ago
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
Compare ORIC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.